Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development

The diagnosis and management of drug‐induced liver injury (DILI) remains a challenge in clinical trials in drug development. The qualification of emerging biomarkers capable of predicting DILI soon after the initiation of treatment, differentiating DILI from underlying liver disease, identifying the...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Sharin E., Avigan, Mark I., Bourdet, David, Brott, David, Church, Rachel, Dash, Ajit, Keller, Douglas, Sherratt, Philip, Watkins, Paul B., Westcott‐Baker, Lucas, Lentini, Silvia, Merz, Michael, Ramaiah, Lila, Ramaiah, Shashi K., Stanley, Ann Marie, Marcinak, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006882/
https://www.ncbi.nlm.nih.gov/pubmed/31314926
http://dx.doi.org/10.1002/cpt.1571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006882/
https://www.ncbi.nlm.nih.gov/pubmed/31314926
http://dx.doi.org/10.1002/cpt.1571

Ejemplares similares